Recent Financings Of Private Companies, October 2014
This article was originally published in Start Up
Executive Summary
Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced August through September 2014.
You may also be interested in...
Finance Watch: Pandion's $55m Series A Funds Localized Bispecifics For Autoimmune Diseases
Pandion, led by former Pfizer SVP Anthony Coyle, launched in 2017 to exploit immuno-oncology advances for autoimmune and inflammatory diseases; the firm's Series A follows a record-breaking year for biopharma venture capital. In public company financings, AveXis and others seek cash to fuel R&D.
Deals In Depth: December 2021
Eight $1bn+ alliances were penned in December. Topping the list was a potential $12.4bn deal between Recursion and Roche (and its Genentech subsidiary) involving the identification and development of small-molecule programs in a gastrointestinal cancer indication and in key areas of neuroscience. Recursion is responsible for creating a certain number of PhenoMaps, which are massive relational databases of biological and chemical perturbation phenotypes. For each of the PhenoMaps requested by Roche, Recursion may be subject to an initiation fee up to $250m for sixteen accepted PhenoMaps. Recursion will receive an up-front payment of $150m and is eligible for additional performance-based research milestones. Roche and Genentech have the option to obtain an exclusive license to initiate up to 40 programs, each of which, if successfully developed and commercialized, could yield more than $300m in development, commercialization, and sales milestones for Recursion.
Deals In Depth: November 2021
Six $1bn+ alliances were penned in November. Topping the list was a potential $2.7bn deal between Neurocrine Biosciences and Sosei Group for the development and commercialization of candidates containing certain sub-type selective muscarinic M1, M4, or dual M1/M4 receptor agonists discovered by Sosei Heptares and in development for neurological disorders, which Neurocrine intends to study in the treatment of schizophrenia, dementia, and other neuropsychiatric disorders. The company gains exclusive worldwide rights to develop, manufacture, and commercialize the candidates, while Sosei retains the rights to develop M1 agonist programs in Japan in all indications, with Neurocrine receiving co-development and profit share options.